Other Ophthalmic Surgery Organ Transplantation Orthopaedics Other Osteoarthritis Osteoporosis Otitis Otorhino. Kytril is the only antiemetic tablet reimbursed by Medi-Cal in doctors' offices. Kytril is also the first and only antiemetic tablet indicated for use with high-dose cisplatin, one of the most emetogenic chemotherapies, with the highest potential of causing nausea and vomiting. Kytril tablets have the same indication as intravenous Kytril , but save the time and preparation costs of intravenous administration. Like intravenous Kytril , Kytril tablets prevent nausea and vomiting associated with a broad range of initial and repeat courses of mild, moderate and highly emetogenic chemotherapies.
Patients are now able to tolerate aggressive, life-saving cancer treatments with minimal nausea.
Also, patients taking Kytril tablets require less nursing and administration time compared to those receiving the intravenous formulation, saving time for both the patient and nursing staff. Medi-Cal's decision to reimburse for Kytril tablets is an important development for the State's cancer patients, according to Dr. Justice. Approximately three quarters of all chemotherapy patients receive treatment in a doctor's office rather than a hospital. Clearly, this broadening of coverage will improve the daily lives of Medi-Cal cancer patients. Studies done in the early 1980's reported that fear of nausea and vomiting are the primary concerns of patients receiving chemotherapy for cancer.